Research ExplorerPublicationsOral fingolimod (FTY720) in relapsing multiple sclerosis: im...

Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.

Standard

Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. / Montalban, X; Comi, G; O'Connor, P; Gold, Stefan; de Vera, A; Eckert, B; Kappos, L.

In: MULT SCLER J, Vol. 17, No. 11, 11, 2011, p. 1341-1350.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Montalban, X, Comi, G, O'Connor, P, Gold, S, de Vera, A, Eckert, B & Kappos, L 2011, 'Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.', MULT SCLER J, vol. 17, no. 11, 11, pp. 1341-1350. <http://www.ncbi.nlm.nih.gov/pubmed/21727148?dopt=Citation>

APA

Montalban, X., Comi, G., O'Connor, P., Gold, S., de Vera, A., Eckert, B., & Kappos, L. (2011). Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. MULT SCLER J, 17(11), 1341-1350. [11]. http://www.ncbi.nlm.nih.gov/pubmed/21727148?dopt=Citation

Vancouver

Montalban X, Comi G, O'Connor P, Gold S, de Vera A, Eckert B et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. MULT SCLER J. 2011;17(11):1341-1350. 11.

Bibtex

@article{5d77c395c3be423faa5d21567fdaa7fa,
title = "Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.",
abstract = "Health-related quality of life (HRQoL) worsens with multiple sclerosis (MS) relapses and disease progression. Common symptoms including depression and fatigue may contribute to poor HRQoL.",
keywords = "Adult, Humans, Male, Female, Middle Aged, Psychiatric Status Rating Scales, Questionnaires, Treatment Outcome, Europe, Time Factors, Double-Blind Method, Placebos, Chi-Square Distribution, Administration, Oral, *Quality of Life, Canada, Depression/drug therapy/etiology, Immunosuppressive Agents/*administration & dosage, Multiple Sclerosis, Chronic Progressive/diagnosis/*drug therapy/psychology, Multiple Sclerosis, Relapsing-Remitting/diagnosis/*drug therapy/psychology, Propylene Glycols/*administration & dosage, Sphingosine/administration & dosage/*analogs & derivatives, Adult, Humans, Male, Female, Middle Aged, Psychiatric Status Rating Scales, Questionnaires, Treatment Outcome, Europe, Time Factors, Double-Blind Method, Placebos, Chi-Square Distribution, Administration, Oral, *Quality of Life, Canada, Depression/drug therapy/etiology, Immunosuppressive Agents/*administration & dosage, Multiple Sclerosis, Chronic Progressive/diagnosis/*drug therapy/psychology, Multiple Sclerosis, Relapsing-Remitting/diagnosis/*drug therapy/psychology, Propylene Glycols/*administration & dosage, Sphingosine/administration & dosage/*analogs & derivatives",
author = "X Montalban and G Comi and P O'Connor and Stefan Gold and {de Vera}, A and B Eckert and L Kappos",
year = "2011",
language = "English",
volume = "17",
pages = "1341--1350",
journal = "MULT SCLER J",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "11",

}

RIS

TY - JOUR

T1 - Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.

AU - Montalban, X

AU - Comi, G

AU - O'Connor, P

AU - Gold, Stefan

AU - de Vera, A

AU - Eckert, B

AU - Kappos, L

PY - 2011

Y1 - 2011

N2 - Health-related quality of life (HRQoL) worsens with multiple sclerosis (MS) relapses and disease progression. Common symptoms including depression and fatigue may contribute to poor HRQoL.

AB - Health-related quality of life (HRQoL) worsens with multiple sclerosis (MS) relapses and disease progression. Common symptoms including depression and fatigue may contribute to poor HRQoL.

KW - Adult

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Psychiatric Status Rating Scales

KW - Questionnaires

KW - Treatment Outcome

KW - Europe

KW - Time Factors

KW - Double-Blind Method

KW - Placebos

KW - Chi-Square Distribution

KW - Administration, Oral

KW - Quality of Life

KW - Canada

KW - Depression/drug therapy/etiology

KW - Immunosuppressive Agents/administration & dosage

KW - Multiple Sclerosis, Chronic Progressive/diagnosis/drug therapy/psychology

KW - Multiple Sclerosis, Relapsing-Remitting/diagnosis/drug therapy/psychology

KW - Propylene Glycols/administration & dosage

KW - Sphingosine/administration & dosage/analogs & derivatives

KW - Adult

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Psychiatric Status Rating Scales

KW - Questionnaires

KW - Treatment Outcome

KW - Europe

KW - Time Factors

KW - Double-Blind Method

KW - Placebos

KW - Chi-Square Distribution

KW - Administration, Oral

KW - Quality of Life

KW - Canada

KW - Depression/drug therapy/etiology

KW - Immunosuppressive Agents/administration & dosage

KW - Multiple Sclerosis, Chronic Progressive/diagnosis/drug therapy/psychology

KW - Multiple Sclerosis, Relapsing-Remitting/diagnosis/drug therapy/psychology

KW - Propylene Glycols/administration & dosage

KW - Sphingosine/administration & dosage/analogs & derivatives

M3 - SCORING: Journal article

VL - 17

SP - 1341

EP - 1350

JO - MULT SCLER J

JF - MULT SCLER J

SN - 1352-4585

IS - 11

M1 - 11

ER -